Amylin presents improved indices of beta-cell function after 3 years of BYETTA therapy Amylin Pharmaceuticals, Inc. 3 years of BYETTA therapy improved indices of beta-cell function assessed a month after discontinuing therapy uncontrollable ejaculation . These findings were presented at the 70th Annual Scientific Classes of the American Diabetes Association in Orlando, Fla. After 3 years of treatment, both therapies decreased A1C similarly . A1C is a measure of average blood sugar over three months. In addition, BYETTA significantly reduced bodyweight compared to Lantus . After completion of 3 years of therapy, a four-week off-medication period followed to permit assessment of parameters of metabolic state including beta-cell function.